H2SITE Secures €3.4 Million (NOK 39.1 million) in Enova Funding to Scale Onboard Ammonia-To-Power for Commercial Maritime Applications
22.9.2026 06:00:00 CEST | Business Wire | Press Release
H2SITE has secured €3.4 million (NOK 39.1 million) in funding from Enova for HydraNord Power, a project that will develop and validate a commercial-scale onboard ammonia-to-power system for the maritime sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921324898/en/
Enova is one of the Norwegian government's primary instruments for accelerating the country's climate and energy transition. Its primary responsibility is to manage the Climate and Energy Fund on behalf of the Norwegian government. For H2SITE, Enova’s support is a major milestone in the commercialisation of its onboard ammonia cracking technology, enabling the company to scale from proven maritime demonstrations to replicable commercial solutions for the global shipping industry.
Led by H2SITE, HydraNord Power will convert ammonia into high-purity hydrogen directly onboard vessels. The system will produce up to one tonne of hydrogen per day and supply maritime fuel cells delivering 700 kW of net electrical power.
The project represents a step-change in scale for H2SITE. It builds on several smaller maritime ammonia-to-hydrogen projects, including units already in operation. With an output representative of commercial auxiliary power requirements onboard vessels, HydraNord Power moves the technology beyond smaller-scale demonstrations and towards repeatable commercial deployment.
H2SITE’s membrane reactor integrates ammonia cracking and hydrogen separation in a single process, producing fuel-cell-grade hydrogen while protecting the fuel cells from ammonia contamination. Its compact and modular architecture is designed for both newbuild and retrofit projects, as well as fuel-cell-only and hybrid power systems. Multiple modules can be deployed in parallel to address larger power requirements, providing a standardised building block for future multi-megawatt installations.
“HydraNord Power takes ammonia-to-power from successful smaller deployments into a commercially relevant power range,” said Andrés Galnares, CEO of H2SITE. “At 700 kW net, we are addressing a real onboard power requirement with a standardised system that can be replicated across vessels and scaled into larger installations. Enova’s support allows us to demonstrate this under representative operating conditions and opens a significant market opportunity in maritime segments where direct electrification is not viable.”
HydraNord Power brings together H2SITE, Equinor, Höegh Autoliners, Breeze Ship Design, Sustainable Energy Catapult Centre, Alltec and Maritime CleanTech. Together, the partners cover vessel requirements, system design, fuel cells, site integration, testing and project coordination, ensuring that the solution is developed around real maritime operating needs rather than as a standalone technology demonstration.
The complete system will be installed and tested at Energy House in Stord, Norway, under conditions representative of commercial maritime operations. Development and integration will take place during 2027, with commissioning planned for early 2028.
HydraNord Power initially targets auxiliary and hybrid power applications in deep-sea shipping, offshore operations and other energy-intensive maritime segments. Its standardised modular design will enable the same core technology to be deployed across different vessel classes and power levels, creating a repeatable path from first commercial installations to broader fleet adoption.
About H2SITE
H2SITE is an industrial technology company and infrastructure partner enabling competitive hydrogen and derivatives solutions for large-scale decarbonisation. Through its proprietary membrane reactor technology, H2SITE delivers scalable, standardised and bankable systems for hydrogen production, separation and ammonia cracking. Designed for industrial deployment, its solutions support efficient hydrogen logistics and decentralised generation models.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260921324898/en/
Contacts
andres.galnares@h2site.com
CEO H2SITE
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mary Kay Introduces the K-Beauty Texture Edit5.10.2026 14:02:00 CEST | Press Release
Mary Kay Inc.,the iconic beauty giant announced today the launch of the K-Beauty Texture Edit, aspecial-edition skin care collection available while supplies last. The collection builds on the momentum of the company's largest consumer-facing global brand platform, Beauty Is More Beautiful Shared™ which launched in September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005600130/en/ Mary Kay's Special Edition K-Beauty Texture Edit is a trend-forward collection which includes three Korea-made products: the Mary Kay® Melt-In Cleansing Balm, Mary Kay® Snail Gel Face Patches and Mary Kay® Collagen Moisturizing Gel. (Image Credit: Mary Kay Inc.) Inspired by Korea's globally influential skin care and self-care philosophy designed to bring playful textures, innovative ingredients, and elevated beauty experiences, the K-Beauty Texture Editwas designed to resonate with a global cultural beauty movement captivating the next gene
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.5.10.2026 14:00:00 CEST | Press Release
GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005273717/en/ SOFIE Biosciences has 15 CMO sites across the U.S., manufacturing PET radiopharmaceutical products The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical ‘final mile’ of U.S. PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio. With a U.S. network of 15 CMO sites operating 21 cyclotrons, and a theranostics
Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 13:24:00 CEST | Press Release
Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking expertise with Solos' proprietary dealcoholization and patented aroma recovery technology. With 30 years of experience in producing alcohol-free sparkling wines, Henkell Fre
Croma-Pharma Expands Its Portfolio in Canada With saypha ® lips Lidocaine and Exprecell™5.10.2026 13:12:00 CEST | Press Release
Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia
Anaeco Secures Strategic Investment from Momentum Global Ventures to Accelerate Commercial Deployment5.10.2026 12:00:00 CEST | Press Release
Anaeco, Inc., a clean technology company developing systems to destroy harmful and difficult-to-abate gases, today announced a strategic investment from Momentum Global Ventures. The investment supports Anaeco as it moves from technology development and validation to commercial deployment across three initial markets: anesthetic gases, refrigerants, and semiconductor manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005546122/en/ Anaeco’s technology exploits atmospheric chemistry to destroy harmful, high-impact gases, including HFCs, PFAS, anesthetic gases, N2O, and other difficult-to-abate emissions at their source. By accelerating processes that naturally transform pollutants, its modular technology provides a practical, scalable approach to emissions that are difficult or costly to manage conventionally. Initial Commercial Verticals Anesthetics: Destroying anesthetic gases generated in healthcare environmen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom